Lucid Diagnostics priced an underwritten registered direct offering of 18 million common shares at $1.00 per share, raising $18 million gross proceeds. The financing is anchored by a $15 million investment from a fundamental institutional investor with support from an existing shareholder. The company said it plans to use proceeds for working capital and general corporate purposes. The offering is expected to close April 24, with Canaccord Genuity and BTIG acting as joint bookrunners. For investors tracking early commercial diagnostics, the update signals near-term liquidity management tied to ongoing development and utilization of its EsoGuard esophageal DNA testing program in GERD patients at risk of esophageal cancer.